Authors: HORIOT JC LIPINSKI F SCHRAUB S MAYLIN C BENSADOUN RJ ARDIET JM BOLLA M COSCAS Y BAILLET F COCHEDEQUEANT B URBAJTEL M MONTBARBON X BOURDIN S WIBAULT P PENE F ALFONSI M CALAIS G DESPREZ P LAPEYRE M VINKE J LABART M SAVARY J

Citation: Jc. Horiot et al., POST RADIATION SEVERE XEROSTOMIA RELIEVED BY PILOCARPINE - A PROSPECTIVE FRENCH COOPERATIVE STUDY, European journal of cancer, 33, 1997, pp. 54-54

Authors: VENTURINI M MICHELOTTI A DELMASTRO L GALLO L CAMINO F GARRONE O TIBALDI C MOLEA N BELLINA RC PRONZATO P CYRUS P VINKE J TESTORE F GUELFI M LIONETTO R BRUZZI P CONTE PF ROSSO R

Citation: M. Venturini et al., MULTICENTER RANDOMIZED CONTROLLED CLINICAL-TRIAL TO EVALUATE CARDIOPROTECTION OF DEXRAZOXANE VERSUS NO CARDIOPROTECTION IN WOMEN RECEIVING EPIRUBICIN CHEMOTHERAPY FOR ADVANCED BREAST-CANCER, Journal of clinical oncology, 14(12), 1996, pp. 3112-3120

Authors: JONES M PHILIP T PALMER P VONDERMAASE H VINKE J ELSON P FRANKS CR SELBY P

Citation: M. Jones et al., THE IMPACT OF INTERLEUKIN-2 ON SURVIVAL IN RENAL-CANCER - A MULTIVARIATE-ANALYSIS, Cancer biotherapy, 8(4), 1993, pp. 275-288

Authors: PALMER PA ATZPODIEN J PHILIP T NEGRIER S KIRCHNER H VONDERMAASE H GEERTSEN P EVERS P LORIAUX E OSKAM R ROEST G VINKE J FRANKS CR

Citation: Pa. Palmer et al., A COMPARISON OF 2 MODES OF ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 - CONTINUOUS INTRAVENOUS-INFUSION ALONE VERSUS SUBCUTANEOUS ADMINISTRATION PLUS INTERFERON-ALPHA IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Cancer biotherapy, 8(2), 1993, pp. 123-136